Case J Brad, Fick Jennifer L, Rooney Matthew B
Department of Surgery, Flatiron Veterinary Specialists, 230 South Main Street, Longmont, Colorado 80501, USA.
J Am Anim Hosp Assoc. 2010 Jul-Aug;46(4):255-8. doi: 10.5326/0460255.
The purpose of this study was to describe the clinical and gross pathological findings, treatment, and outcome in three dogs receiving deracoxib that developed proximal duodenal perforation and subsequent septic peritonitis. Clinical findings were acute vomiting and anorexia following initiation of deracoxib therapy. Deracoxib dosages ranged from 2 to 3 mg/kg per os q 24 hours. In each dog, exploratory laparotomy revealed duodenal perforations approximately 1 cm orad to the major duodenal papilla. Two out of three dogs survived following exploratory laparotomy. Two of three dogs in the present case series received the approved deracoxib dosage. Dogs receiving deracoxib, even at labeled dosages, should be monitored judiciously for signs of gastrointestinal disease.
本研究的目的是描述三只接受德拉考昔治疗后发生十二指肠近端穿孔及随后的化脓性腹膜炎的犬的临床和大体病理表现、治疗及预后情况。临床症状为开始使用德拉考昔治疗后出现急性呕吐和厌食。德拉考昔剂量为每24小时口服2至3毫克/千克。每只犬经剖腹探查均发现十二指肠穿孔位于十二指肠大乳头口侧约1厘米处。三只犬中有两只在剖腹探查后存活。本病例系列中的三只犬中有两只接受了批准的德拉考昔剂量。即使是接受标记剂量的德拉考昔的犬，也应谨慎监测其胃肠道疾病的体征。
